Contrary To Misinformation, COVID-19 Mortality And Hospitalization Has Been Rising In The Last 30 Days Globally. Please Take Precautions!

  Oct 01, 2018
  Oct 01, 2018

10mg (5mg/mL)

(Somatropin (INN) recombinant DNA origin, Escherichia coli.)
Consumer Medicine Information

What is in this leaflet?

Please read this leaflet carefully before you use NutropinAq.
This leaflet answers some common questions about NutropinAq. It does not contain all the available information. It does not take the place of talking to your doctor or pharmacist.
All medicines have risks and benefits. Your doctor has weighed the risks of you using NutropinAq against the benefits he/she expects it will have for you.
If you have any concerns about using this medicine, ask your doctor or pharmacist.
Keep this leaflet with the medicine. You may need to read it again.

What is NutropinAq?

The active substance of NutropinAq is somatropin. Somatropin is human growth hormone, which is made by genetic engineering using the bacterial micro-organism Escherichia coli. The structure of somatropin is identical to human growth hormone of pituitary origin.
Somatropin has effects that are equivalent to human growth hormone of pituitary origin. Growth hormone exerts significant effects directly on the production of other hormones, e.g. IGF-1, and on metabolic actions. The anabolic and growth-promoting effects of somatropin are in some part indirect effects mediated by IGF-1.

What NutropinAq is used for?

NutropinAq is used for:
Long-term treatment of children with growth failure due to inadequate endogenous growth hormone secretion.
Long-term treatment of growth failure associated with Turner syndrome.
Treatment of prepubertal children with growth failure associated with chronic renal insufficiency up to the time of renal transplantation.
Replacement of growth hormone in adults with growth hormone deficiency originating in either childhood or adulthood.
Ask your doctor if you have any questions why NutropinAq has been prescribed for you.
Your doctor may have prescribed it for another reason.

Before you use NutropinAq

Do not use NutropinAq:

in case of hypersensitivity to somatropin or any of the other ingredients
for growth promotion if growing is already finished
if an active tumour (cancer) is present. Tell your doctor if you have or have had an active tumour. Tumours must be inactive and you must have finished your anti-tumour treatment before you start your treatment with NutropinAq.
during acute critical illness due to complications following open-heart or abdominal surgery, multiple accidental trauma or in case of acute respiratory failure.
Treatment with NutropinAq should be discontinued if evidence of tumour growth develops.
Treatment with NutropinAq should be initiated and monitored by adequately experienced physicians.

Before you start to use it

Tell your doctor if:
you have diabetes
you have been diagnosed with Prader-Willi Syndrome
you have long term kidney disease
you have diabetes and worsening or severe eye disease
you have problems with your thyroid
you have any other hormone problems
you are on a controlled sodium diet. NutropinAq contains 8.2mg of sodium per cartridge.
If you have had a tumour (cancer) in the past, especially a tumour affecting the brain, your doctor should pay special attention and examine you regularly for a possible return of the tumour. A small number of growth hormone deficient patients treated with growth hormone have had leukaemia (blood cancer). However, no cause and effect relationship with growth hormone treatment has been proven.
There may be an increased risk of developing an inflammation of the pancreas (pancreatitis) in children compared to adults treated with growth hormone. In case of severe and persistent abdominal pain, consult your doctor.

While you are using NutropinAq

Please ask the doctor for advice if you develop a limp or if you experience hip or knee pain.
If you have diabetes mellitus, please consult the doctor regularly during treatment with NutropinAq. Your insulin dose may require adjustment after treatment with NutropinAq is started.
Tell the doctor if you experience any visual changes, headache, nausea and/or vomiting, especially within the first eight weeks after starting treatment with NutropinAq.
Scoliosis (abnormal curve of the spine) may progress in any child during rapid growth. Your doctor should monitor you for any signs of scoliosis during treatment.
If you undergo a kidney transplant, NutropinAq treatment should be stopped.
If you are taking replacement therapy with glucocorticoids you should consult your doctor regularly as you may need adjustments of your glucocorticoid dose.
Your doctor may take blood tests during treatment to check your blood count.


Treatment with NutropinAq should be discontinued if pregnancy occurs. Please ask your doctor or pharmacist for advice before taking any medicine.


It is not known whether NutropinAq is excreted in human milk. However, absorption of intact protein from the gastrointestinal tract of the infant is unlikely. Please ask your doctor or pharmacist for advice before taking any medicine.

Driving and using machines:

No studies on the effects of NutropinAq on the ability to drive and use machines have been performed.
NutropinAq has no known effect on the ability to drive or to use machines.

Taking other medicines

Tell your doctor or pharmacist if you are taking any other medicines, including any that you buy without a prescription at your pharmacy, supermarket or health food shop.
NutropinAq and some medicines may interfere with the actions of each other, as listed below:
Concomitant treatment with glucocorticoids may reduce the growth-promoting effect of NutropinAq
NutropinAq may reduce insulin sensitivity, therefore patients with diabetes mellitus may require adjustment of their anti-diabetic therapy
During concomitant administration of NutropinAq with corticosteroids, sex steroids, anticonvulsants or cyclosporin, the effect of treatment with these medicines may be affected. Please ask the doctor for advice
Previously undiagnosed adrenal insufficiency may become apparent and require steroid treatment. Patients already treated for adrenal insufficiency may require adjustment of dose during NutropinAq treatment.
Your doctor or pharmacist has more information on medicines to be careful with or avoid while using this medicine.

How to use NutropinAq

How much and how often is it given?

The doctor will advise you about the individualised dose of NutropinAq. Please do not change the dosage without consulting the doctor or pharmacist. In general the dosage will be calculated according to the following rules:
Growth failure in children due to inadequate growth hormone secretion:
0.025 - 0.035 mg/kg bodyweight given as a daily subcutaneous injection.
Growth failure associated with Turner syndrome:
Up to 0.05 mg/kg bodyweight given as a daily subcutaneous injection.
Growth failure associated with chronic renal insufficiency:
Up to 0.05 mg/kg bodyweight given as a daily subcutaneous injection.
Treatment with NutropinAq may be continued up to the time of renal transplantation.
Growth hormone deficiency in adults:
Low initial doses of 0.15 - 0.3 mg given as a daily subcutaneous injection. The dose may be increased stepwise by the doctor according to the patient's individual requirements. The final dose seldom exceeds 1.0 mg/day. In general, the lowest efficacious dose should be received. For older or overweight patients lower doses may be necessary.
NutropinAq is designed for use only with the NutropinAq Pen. The product is for use in one individual only.
Please administer the prescribed dose of NutropinAq solution for injection subcutaneously each day and change the site of injection each time. At the start of treatment it is recommended that a doctor or a nurse give the injection. After training the injection can be given by the patient or his/her carer. The medicine is supplied in a cartridge as a sterile solution with preservative for multiple use. For each single injection please use a new, sterile injection needle. Do not use the solution unless it is clear and not cloudy. Please see also the instructions for use
Treatment with NutropinAq is a long-term therapy, for further information please ask the doctor.

If you forget to use it

After missing an individual dose a double dose should not be injected. The prescribed dosage regimen should be continued.

If you use more than you should (overdose)

If more NutropinAq than recommended was injected, please consult the doctor.
Acute overdose could lead initially to a glucose decrease (hypoglycaemia) and subsequently to a glucose increase (hyperglycaemia). Long-term overdose may result in an enhanced growth of ears, nose, lips, tongue and cheekbone (gigantism and/or acromegaly). These signs are consistent with the known effects of excess in human growth hormone.

Effects when treatment is stopped:

A disruption or early ending of the treatment with NutropinAq may impair the success of the growth hormone therapy. Please ask the doctor for advice before stopping the treatment.

Side effects

Tell your doctor or pharmacist as soon as possible if you do not feel well while you are using NutropinAq.
Like all medicines, NutropinAq can have side effects. Generally these are mild but you may need medical attention if you get some of the side effects.
Very common side effects (affecting more than 1 patient in 10):
Accumulation of fluids in the body (oedema) with swelling of the hands and feet (peripheral oedema), muscle pain (myalgia) and pain in one or more joints (arthralgia) in adults.
Common side effects (affecting between 1 and 10 patients in 100):
Feeling of weakness (asthenia)
Injection site reactions
Underactivity of the thyroid gland (hypothyroidism)
Increased muscle tone (hypertonia)
Impaired glucose tolerance
Development of antibodies to the protein somatropin
Pain in one or more joints(arthralgia), muscle pain (myalgia), accumulation of fluids in the body (oedema) and swelling of the hands and feet (peripheral oedema) in children.
Other common side effects which are specific to the disease which NutropinAq is being used to treat are listed below:
Children with growth failure due to growth hormone deficiency:
Tumours, including malignant tumours, have occurred, particularly in patients previously diagnosed with cancer.
Children with growth failure associated with Turner Syndrome:
Common: abnormally heavy bleeding at menstruation (menorrhagia)
Children with growth failure due to chronic renal insufficiency:
Common: Renal failure (kidney dysfunction), peritonitis (inflammation of the lining of the abdomen), bone necrosis, increase in creatinine blood levels.
Children with chronic renal insufficiency were more likely to develop increased pressure in the brain (intracranial hypertension).
Adults with growth hormone deficiency:
Very common: abnormal sensations of tingling, pricking or numbness (paraesthesia).
Common: Increase in blood glucose (hyperglycaemia), increase in blood lipids (hyperlipidaemia), sleeplessness (insomnia), joint disorders, arthrosis (degenerative joint disease), muscle weakness, back pain, breast pain, breast enlargement (gynaecomastia).
Other side effects not listed above may also occur in some people.
If any side effects are noticed which are not mentioned in the leaflet, please inform the doctor or pharmacist.
If any side effect becomes troublesome or causes concern, tell your doctor immediately or go to the Accident and Emergency department at your nearest hospital. You may need medical attention.

How to store NutropinAq


Keep out of the reach and sight of children.
Store at 2°C-8°C. Do not freeze.
Keep the container in the outer carton. Protect from light.
After first use, the cartridge may be stored for up to 28 days at 2°C-8°C. Do not remove the cartridge that is being used from the NutropinAq Pen between injections.
Do not use after the expiry date stated on the label of the cartridge and the carton.
Do not use NutropinAq if you notice that the solution is cloudy.


If your doctor tells you to stop treatment or the medicine has passed its expiry date, ask your pharmacist what to do with any medicine that is left over.

Product Description

What it looks like

NutropinAq 10 mg (5mg/mL) solution for injection in a cartridge.
NutropinAq is a solution for subcutaneous use. The clear, colourless, sterile solution for multidose use is contained in a cartridge of glass, closed with a rubber stopper and a rubber seal.
NutropinAq is available in pack sizes of 1 and 3 cartridges.


Each cartridge of NutropinAq contains 2 mL of solution with a total of 10 milligrams corresponding to 30 International Units (IU) of the active substance somatropin.
The other ingredients are sodium chloride, phenol, polysorbate 20, sodium citrate, citric acid anhydrous and water for injections